https://www.endogenytx.com/science daily 0.75 2026-01-12 https://images.squarespace-cdn.com/content/v1/5ee04e00ca968905fcd3a4b2/1591796080692-VFRF73IQYMHCL6XD6A5T/new+growth.jpg Science - Pipeline We have identified two priority targets in the R&D phase which exhibit anti-inflammatory, anxiolytic, antidepressant, and antiseizure effects. more… https://images.squarespace-cdn.com/content/v1/5ee04e00ca968905fcd3a4b2/1591796589960-FATVWM05DDE74FKAZMD9/hope+for+growth.jpg Science - Patients Our lead targets are based on clinically effective drugs and evidence-based identification of endogenous targets with anti-inanxiolytic, antidepressant, and antiseizure effects. more… https://images.squarespace-cdn.com/content/v1/5ee04e00ca968905fcd3a4b2/1591796131412-HG5H1NIV00EB8RSIKH71/continued+growth.jpg Science - Portfolio Our portfolio focuses on harnessing endogenous targets with well-established therapeutic effects. more… https://www.endogenytx.com/endogeny daily 0.75 2024-03-10 https://www.endogenytx.com/pipeline daily 0.75 2020-06-10 https://images.squarespace-cdn.com/content/v1/5ee04e00ca968905fcd3a4b2/1591822189670-S61RHG16UV2P2T5619U9/increasing+growth+3.jpg Pipeline https://images.squarespace-cdn.com/content/v1/5ee04e00ca968905fcd3a4b2/1591822285447-3CU13FNTMYVUZ76WP42K/increasing+growth+2.jpg Pipeline https://images.squarespace-cdn.com/content/v1/5ee04e00ca968905fcd3a4b2/1591822305129-PYC7UAXQYUVKISSC8W48/increasing+growth+1.jpg Pipeline https://www.endogenytx.com/patients daily 0.75 2020-06-10 https://www.endogenytx.com/home daily 1.0 2020-06-10 https://www.endogenytx.com/team daily 0.75 2020-06-11 https://images.squarespace-cdn.com/content/v1/5ee04e00ca968905fcd3a4b2/1591833976885-U7J1OLKA3CMD1PYMEN2I/high-res-181108_6285_maguire019a.png Team - Jamie Maguire, PhD Founder of Endogeny Therapeutics https://www.endogenytx.com/portfolio daily 0.75 2020-06-10 https://www.endogenytx.com/contactus daily 0.75 2024-03-11